<p><strong>赞助有助于扩展经过验证的 Alpha-1 检测策略，从而实现更早的患者识别</strong></p>
<p>, /PRNewswire/ -- AlphaDetect 是一个由 Alpha-1 基金会支持和资助的非营利组织，今天宣布赛诺菲作为其首批行业赞助商之一。这一支持进一步加强了加速常规检测 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的努力，与临床实践指南一致。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg"/></p>
<p>AlphaDetect 致力于通过提升意识、消除障碍和扩大临床实践指南中检测建议的采用，识别所有面临这种渐进性遗传疾病风险的人，以便 Alpha-1 检测成为受肺部和肝脏疾病影响患者的常规做法。该组织正在增加 Alpha-1 检测工具和支持在实践层面的可用性，同时与医疗服务提供者合作，战略性地推进医疗系统中的协议和技术。</p>
<p>&#34;赛诺菲很自豪能够支持 AlphaDetect 的使命，作为首批赞助商之一，增加和加速 Alpha-1 检测，&#34; 赛诺菲罕见疾病全球医学事务负责人 Alaa Hamed 说。&#34;这一努力代表了在揭示那些面临这种极度未被诊断的罕见疾病风险的人的重要一步，这种疾病可能会产生毁灭性的影响。这一合作反映了我们对 Alpha-1 社区的承诺，特别是在推动意识和认可方面。确保患有这种潜在遗传疾病的人能够在其护理旅程中更早地发现这一诊断，对他们获得更好结果的机会至关重要。我们期待与 AlphaDetect 在这一重要努力中合作。&#34;</p>
<p>&#34;Alpha-1 是一种渐进性遗传性肺部和肝脏疾病，检测延迟可能会产生真实且不可逆转的后果，&#34; AlphaDetect 首席执行官 Julie Murray 说。&#34;快速和系统地扩大识别高风险患者的有效方法，可以为受影响者提供及时的决策信息。赛诺菲的支持和承诺是重要且令人感激的，因为我们继续推进 Alpha-1 检测。&#34;</p>
<p>Alpha-1 仍然显著未被诊断，估计超过 90% 的受影响个体尚未被识别。它也是已知的慢性阻塞性肺病（COPD）的主要遗传风险因素，并与儿童和成人的肝病相关。重要的是，检测还提供了进入 Alpha-1 社区的切入点，为未来的旅程打开了获取全面信息、支持和资源的大门。</p>
<p>&#34;这一支持建立在赛诺菲对罕见疾病和 Alpha-1 社区的承诺之上，&#34; Alpha-1 基金会首席执行官 Scott Santarella 说。&#34;这也代表了我们在检测方法上向前迈出的重要一步。通过通过 AlphaDetect 扩大这些努力，我们可以更早地识别更多个体，并实现 Alpha-1 基金会改善他们生活的使命。&#34;</p>
<p>最新的临床指南建议对所有患有 COPD、治疗抵抗性哮喘或原因不明的肝病的个体进行 Alpha-1 检测。然而，现实世界的结果远远低于这一标准。AlphaDetect 致力于缩小这一差距。赛诺菲的赞助和承诺将帮助 AlphaDetect 扩大提供者教育、拓宽检测策略，并在 Alpha-1 社区内合作，识别患有 Alpha-1 的个体。</p>
<p><strong>关于 AlphaDetect</strong></p>
<p>AlphaDetect 成立于 2025 年，加速检测以揭示所有在遗传上面临 Alpha-1 风险的人。AlphaDetect 位于北卡罗来纳州达勒姆，将作为有限责任公司和 Alpha-1 基金会的非营利子公司运营，享有根据《国内税收法》第 501(c) 3 条款的免税地位。</p>
<p>欲了解更多信息，请访问 https://alpha1.org/alphadetect/</p>
<p>联系人：Cindy Machles</p>
<p>cmachles@alphadetect.org</p>
<p><strong>关于赛诺菲</strong></p>
<p>赛诺菲是一家以研发为驱动、以人工智能为动力的生物制药公司，致力于改善人们的生活并实现可持续增长。我们运用对免疫系统的深刻理解，发明治疗和保护全球数百万人的药物和疫苗，拥有一条创新的产品管线，可能使更多人受益。我们的团队以一个目标为指导：追求科学的奇迹以改善人们的生活；这激励我们推动进步，为我们服务的人民和社区带来积极影响，解决我们时代最紧迫的医疗、环境和社会挑战。赛诺菲在 EURONEXT: SAN 和 NASDAQ: SNY 上市。</p>
<p>欲了解更多信息，请访问 www.sanofi.com</p>
<p>联系人：Evan Berland</p>
<p>evan.berland@sanofi.com</p>
<p><strong>关于 Alpha-1 基金会</strong></p>
<p>Alpha-1 基金会成立于 1995 年，致力于寻找 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的治愈，并改善全球受该疾病影响的人的生活。A1F 已投资超过 1 亿美元支持北美、欧洲、中东和澳大利亚 130 个机构的 Alpha-1 研究和项目。</p>
<p>欲了解更多信息，请访问 alpha1.org</p>
<p>联系人：Jeanne Kushner</p>
<p>jkushner@alpha1.org</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973907/Sanofi.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973907/Sanofi.jpg"/></p>
<p>来源：Alpha-1 基金会</p>

赛诺菲

赛诺菲集团

<p>赛诺菲已成为 AlphaDetect 的首批赞助商，该组织是一家专注于加速阿尔法-1 抗胰蛋白酶缺乏症（Alpha-1）检测的非营利组织。此次合作旨在提高对这一被低估的遗传疾病的认识和检测，该疾病对肺部和肝脏健康有显著影响。赛诺菲的支持将有助于扩展检测策略，并通过确保早期诊断来改善患者的治疗结果。Alpha-1 仍然在很大程度上未被诊断，超过 90% 的受影响个体尚未被识别。这一合作反映了赛诺菲对 Alpha-1 社区和罕见疾病倡议的承诺</p>

<p><strong>The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification</strong></p>
<div class="lb-trans"><p><strong>赞助有助于扩展经过验证的 Alpha-1 检测策略，从而实现更早的患者识别</strong></p>
</div><p>, /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation, today announced Sanofi as one of its inaugural industry sponsors. This support further strengthens efforts to accelerate routine detection of Alpha-1 Antitrypsin Deficiency (Alpha-1), consistent with clinical practice guidelines.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- AlphaDetect 是一个由 Alpha-1 基金会支持和资助的非营利组织，今天宣布赛诺菲作为其首批行业赞助商之一。这一支持进一步加强了加速常规检测 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的努力，与临床实践指南一致。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg"/></p>
<p>AlphaDetect is dedicated to identifying everyone at risk for this progressive, genetic condition by elevating awareness, removing barriers, and expanding adoption of testing recommendations in clinical practice guidelines, so that Alpha-1 detection becomes routine for patients impacted by lung and liver disease. The organization is increasing the availability of Alpha-1 detection tools and support at the practice level while partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems.</p>
<div class="lb-trans"><p>AlphaDetect 致力于通过提升意识、消除障碍和扩大临床实践指南中检测建议的采用，识别所有面临这种渐进性遗传疾病风险的人，以便 Alpha-1 检测成为受肺部和肝脏疾病影响患者的常规做法。该组织正在增加 Alpha-1 检测工具和支持在实践层面的可用性，同时与医疗服务提供者合作，战略性地推进医疗系统中的协议和技术。</p>
</div><p>&#34;Sanofi is proud to support AlphaDetect's mission, as one of the inaugural sponsors, to increase and accelerate Alpha-1 detection,&#34; said Alaa Hamed, Global Head of Medical Affairs, Rare Diseases at Sanofi. &#34;This effort represents a meaningful step forward in uncovering those at risk for this extremely underdiagnosed rare disease, which can have a devastating impact. This collaboration reflects our commitment to the Alpha-1 community, particularly in driving awareness and recognition. Ensuring that people who have this underlying genetic condition can uncover this diagnosis earlier in their care journey is fundamental to their chance of better outcomes. We look forward to working with AlphaDetect on this important effort.&#34;</p>
<div class="lb-trans"><p>&#34;赛诺菲很自豪能够支持 AlphaDetect 的使命，作为首批赞助商之一，增加和加速 Alpha-1 检测，&#34; 赛诺菲罕见疾病全球医学事务负责人 Alaa Hamed 说。&#34;这一努力代表了在揭示那些面临这种极度未被诊断的罕见疾病风险的人的重要一步，这种疾病可能会产生毁灭性的影响。这一合作反映了我们对 Alpha-1 社区的承诺，特别是在推动意识和认可方面。确保患有这种潜在遗传疾病的人能够在其护理旅程中更早地发现这一诊断，对他们获得更好结果的机会至关重要。我们期待与 AlphaDetect 在这一重要努力中合作。&#34;</p>
</div><p>&#34;Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences, &#34; said Julie Murray, CEO of AlphaDetect. &#34;The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Sanofi are important and appreciated as we continue to advance Alpha-1 detection.&#34;</p>
<div class="lb-trans"><p>&#34;Alpha-1 是一种渐进性遗传性肺部和肝脏疾病，检测延迟可能会产生真实且不可逆转的后果，&#34; AlphaDetect 首席执行官 Julie Murray 说。&#34;快速和系统地扩大识别高风险患者的有效方法，可以为受影响者提供及时的决策信息。赛诺菲的支持和承诺是重要且令人感激的，因为我们继续推进 Alpha-1 检测。&#34;</p>
</div><p>Alpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified. It is also the leading known genetic risk factor for COPD and is associated with liver disease in both children and adults. Importantly, detection also provides a point of entry into the Alpha-1 community, opening the door to the comprehensive information, support, and resources needed for the journey ahead.</p>
<div class="lb-trans"><p>Alpha-1 仍然显著未被诊断，估计超过 90% 的受影响个体尚未被识别。它也是已知的慢性阻塞性肺病（COPD）的主要遗传风险因素，并与儿童和成人的肝病相关。重要的是，检测还提供了进入 Alpha-1 社区的切入点，为未来的旅程打开了获取全面信息、支持和资源的大门。</p>
</div><p>&#34;This support builds on Sanofi's commitment to rare disease and the Alpha-1 community,&#34; said Scott Santarella, CEO of the Alpha-1 Foundation. &#34;It also represents an important step forward in how we approach detection. By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on the Alpha-1 Foundation's mission of improving their lives.&#34;</p>
<div class="lb-trans"><p>&#34;这一支持建立在赛诺菲对罕见疾病和 Alpha-1 社区的承诺之上，&#34; Alpha-1 基金会首席执行官 Scott Santarella 说。&#34;这也代表了我们在检测方法上向前迈出的重要一步。通过通过 AlphaDetect 扩大这些努力，我们可以更早地识别更多个体，并实现 Alpha-1 基金会改善他们生活的使命。&#34;</p>
</div><p>The latest clinical guidelines recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. Yet real-world results fall far short of this. AlphaDetect is committed to closing the gap. Sanofi's sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community to identify individuals with Alpha-1.</p>
<div class="lb-trans"><p>最新的临床指南建议对所有患有 COPD、治疗抵抗性哮喘或原因不明的肝病的个体进行 Alpha-1 检测。然而，现实世界的结果远远低于这一标准。AlphaDetect 致力于缩小这一差距。赛诺菲的赞助和承诺将帮助 AlphaDetect 扩大提供者教育、拓宽检测策略，并在 Alpha-1 社区内合作，识别患有 Alpha-1 的个体。</p>
</div><p><strong>About</strong> <strong>AlphaDetect</strong></p>
<div class="lb-trans"><p><strong>关于 AlphaDetect</strong></p>
</div><p>AlphaDetect, founded in 2025, accelerates detection to uncover everyone genetically at risk for Alpha-1. Located in Durham, NC, AlphaDetect will operate as a limited liability company and a non-profit subsidiary of Alpha-1 Foundation, holding tax-exempt status under Section 501(c) 3 of the Internal Revenue Code.</p>
<div class="lb-trans"><p>AlphaDetect 成立于 2025 年，加速检测以揭示所有在遗传上面临 Alpha-1 风险的人。AlphaDetect 位于北卡罗来纳州达勒姆，将作为有限责任公司和 Alpha-1 基金会的非营利子公司运营，享有根据《国内税收法》第 501(c) 3 条款的免税地位。</p>
</div><p>For more information, visit https://alpha1.org/alphadetect/</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 https://alpha1.org/alphadetect/</p>
</div><p>Contact: Cindy Machles</p>
<div class="lb-trans"><p>联系人：Cindy Machles</p>
</div><p>cmachles@alphadetect.org</p>
<div class="lb-trans"><p>cmachles@alphadetect.org</p>
</div><p><strong>About Sanofi</strong></p>
<div class="lb-trans"><p><strong>关于赛诺菲</strong></p>
</div><p>Sanofi is an R&amp;D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY</p>
<div class="lb-trans"><p>赛诺菲是一家以研发为驱动、以人工智能为动力的生物制药公司，致力于改善人们的生活并实现可持续增长。我们运用对免疫系统的深刻理解，发明治疗和保护全球数百万人的药物和疫苗，拥有一条创新的产品管线，可能使更多人受益。我们的团队以一个目标为指导：追求科学的奇迹以改善人们的生活；这激励我们推动进步，为我们服务的人民和社区带来积极影响，解决我们时代最紧迫的医疗、环境和社会挑战。赛诺菲在 EURONEXT: SAN 和 NASDAQ: SNY 上市。</p>
</div><p>For more information, visit www.sanofi.com</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.sanofi.com</p>
</div><p>Contact: Evan Berland</p>
<div class="lb-trans"><p>联系人：Evan Berland</p>
</div><p>evan.berland@sanofi.com</p>
<div class="lb-trans"><p>evan.berland@sanofi.com</p>
</div><p><strong>About the Alpha-1 Foundation</strong></p>
<div class="lb-trans"><p><strong>关于 Alpha-1 基金会</strong></p>
</div><p>The Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by the condition worldwide. A1F has invested over $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East , and Australia.</p>
<div class="lb-trans"><p>Alpha-1 基金会成立于 1995 年，致力于寻找 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的治愈，并改善全球受该疾病影响的人的生活。A1F 已投资超过 1 亿美元支持北美、欧洲、中东和澳大利亚 130 个机构的 Alpha-1 研究和项目。</p>
</div><p>For more information, visit alpha1.org</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 alpha1.org</p>
</div><p>Contact: Jeanne Kushner</p>
<div class="lb-trans"><p>联系人：Jeanne Kushner</p>
</div><p>jkushner@alpha1.org</p>
<div class="lb-trans"><p>jkushner@alpha1.org</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973907/Sanofi.jpg" alt="" original-src="https://mma.prnewswire.com/media/2973907/Sanofi.jpg"/></p>
<p>SOURCE Alpha-1 Foundation</p>
<div class="lb-trans"><p>来源：Alpha-1 基金会</p>
</div>

赛诺菲支持 AlphaDetect 以加速 Alpha-1 的检测 | 赛诺菲股票新闻